Johnson & Johnson is expected to be far from providing 10 million dosesBy the end of February, 4 million of this product will be ready for shipment after obtaining an emergency use permit approved by the U.S. Food and Drug Administration (FDA).
The shortage disclosed by Johnson & Johnson is the first public indicator of how accurate the pharmaceutical company is behind its production targets. Johnson & Johnson promised to deliver another 25 million vehicles by the end of March.
Dr. Richard Nettles of Johnson & Johnson said: “We will provide 20 million doses of vaccine by the end of March 2000, and we are ready to ship nearly 4 million doses of our vaccine immediately after emergency use authorization.”
He said that by the end of June, the company was still “full of confidence” in the “we provide 100 million doses” vaccine plan.
As a single-dose vaccine that can be stored at standard refrigerator temperatures for three months, although Johnson & Johnson’s efficacy is slightly lower than that of the two-dose vaccine produced by Pfizer, it has been considered a key development in vaccine research in the United States. Moderna.
“This is a vaccine that is very easy to transport and manage; it does not have all these complicated requirements, especially Pfizer, which is a more sophisticated vaccine. It can be done in a single dose. This is the vaccine I want. “Said Dr. Marcus Plescia, Chief Medical Officer of the Association of National and Territorial Health Officials.
Although the vaccine is logically simpler, states may encounter obstacles in deciding which stronger dose locations should be prioritized or how to deal with residents who want one vaccine over another. After the immunization practice advisory committee of the Centers for Disease Control and Prevention meets to discuss the Johnson & Johnson version, some guidance may be released this weekend.
Prescia said: “I think it feels like that in many jurisdictions. It would be great if this vaccine comes with very clear advice on who should get it and how to use it.”
The states still don’t know how many times they should expect Johnson & Johnson. The Biden administration expects to be able to distribute 2 million doses to various jurisdictions next week.
Both Johnson & Johnson and federal officials have admitted for weeks that the company faces obstaclesIn the United States, prompting the government .
Last year, prior to obtaining FDA approval, states received specific allocations for Pfizer and Moderna vaccines.
“Generally speaking, we plan to prepare after the EUA is approved. This is not to be placed in front of the EUA, but to ensure that everything is locked so that when the EUA makes a decision, it is immediately distributed to the United States within 24 hours. People.” Gus Perna, the Trump administration’s head of vaccine distribution, told reporters last year.
In contrast, Biden administration officials declined this week to provide the specific doses they expect from Johnson & Johnson, and the expected distributions from the states are much smaller. When asked whether to keep certain doses in pharmacies or other federal programs, the US government said on Monday that it was waiting to finalize its strategy only after the FDA and CDC weighed in.
White House senior adviser Andy Slavitt (Andy Slavitt) said: “Once we understand what the scientific community is saying, we can answer the very relevant questions we need scientists to ask.”